medi-565
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT01284231)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E activator
- T-cell surface glycoprotein CD3 epsilon chainCROSS-LINKING AGENT
CD3E cross-linking agent
- Carcinoembryonic antigen-related cell adhesion molecule 5CROSS-LINKING AGENT
CEACAM5 cross-linking agent
CEACAM5 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109372 ↗
Also known as
- medi-565
- medi-565
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01284231 | Phase 1 | Dec 1, 2010 | MedImmune |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1